Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China flag China · Delayed Price · Currency is CNY
99.93
+3.13 (3.23%)
May 29, 2026, 3:00 PM CST

SHA:688266 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
2,2182,0312,1542,110797.051,137
Trading Asset Securities
465.53-40.5137.02248.9365.26
Cash & Short-Term Investments
2,6842,0312,1942,2471,0461,202
Cash Growth
25.61%-7.43%-2.34%114.79%-12.97%-24.86%
Accounts Receivable
190.58154.25143.63101.1488.9962.37
Other Receivables
10.5310.279.3810.8912.5112.45
Receivables
201.11164.52153.01112.03101.574.82
Inventory
178.26173.27182.86110.8598.9851.91
Other Current Assets
95.9174.1345.8550.7945.377.33
Total Current Assets
3,1592,4432,5762,5201,2921,406
Property, Plant & Equipment
495.2485.89363.43271.21247.09188.91
Long-Term Investments
---5.991010
Other Intangible Assets
26.9230.5950.0169.2791.03116.29
Long-Term Deferred Charges
4.95.9811.3916.3920.9613.03
Other Long-Term Assets
2.453.633.884.027.4811.78
Total Assets
3,6882,9693,0052,8871,6681,746
Accounts Payable
265.1244.16197.1137.73151.72118.19
Accrued Expenses
55.7689.5286.2282.0267.548.22
Short-Term Debt
842.99989.05951.86795.16390.79131.81
Current Portion of Long-Term Debt
51.1142.14.9750.5650.0430.03
Current Portion of Leases
-9.0111.213.1713.6913.55
Current Income Taxes Payable
37.4313.9720.9520.6420.2918.58
Current Unearned Revenue
46.791.25--0.280.36
Other Current Liabilities
39.3438.88101.1535.8934.8820.16
Total Current Liabilities
1,3391,4281,3731,135729.19380.89
Long-Term Debt
848444.35-50.09-
Long-Term Leases
7.518.626.8629.4643.1848.18
Long-Term Unearned Revenue
8.078.079.211.5545.0448.05
Long-Term Deferred Tax Liabilities
0.651.645.79.5813.3215.77
Other Long-Term Liabilities
536.58358.49292.4556.6--
Total Liabilities
1,9751,8891,7521,242880.82492.88
Common Stock
264.71264.71264.71264.71240240
Additional Paid-In Capital
3,1093,1093,1203,3532,2222,205
Retained Earnings
-1,647-2,280-2,117-1,979-1,700-1,243
Comprehensive Income & Other
-14.05-14.05-14.47-5.95-2.84-6.32
Total Common Equity
1,7131,0801,2541,633759.121,196
Minority Interest
---1.2611.9828.3756.76
Shareholders' Equity
1,7131,0801,2531,645787.491,253
Total Liabilities & Equity
3,6882,9693,0052,8871,6681,746
Total Debt
985.611,1331,039888.35547.8223.57
Net Cash (Debt)
1,698898.421,1551,358498.18978.32
Net Cash Growth
49.98%-22.21%-14.97%172.65%-49.08%-36.78%
Net Cash Per Share
6.413.424.365.312.084.08
Filing Date Shares Outstanding
264.69264.71264.71264.71264.49240
Total Common Shares Outstanding
264.69264.71264.71264.71240240
Working Capital
1,8201,0151,2021,385562.571,025
Book Value Per Share
6.474.084.746.173.164.98
Tangible Book Value
1,6861,0501,2041,564668.091,080
Tangible Book Value Per Share
6.373.974.555.912.784.50
Buildings
-138.34135.2641.9341.9341.21
Machinery
-158.18145.53120.48121.7496.02
Construction In Progress
-275.93123.47135.8386.6727.25